Dossier assessment
Trastuzumab emtansine - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Report documents
-
Extract of dossier assessment
Trastuzumab emtansine - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
-
Dossier assessment
Trastuzumab emtansine - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Press releases
Trastuzumab emtansine: indication of major added benefit in metastatic breast cancer with previous anthracycline therapy
Added benefit not proven in three further subpopulations because appropriate comparator therapies were not implemented
Additional information
Federal Joint Committee (G-BA)
2014-06-19 A G-BA decision was published.
Project details
- Project no.
- A14-01
- Commission
- Commission awarded on 27.11.2013 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Trastuzumab emtansine (breast cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed